[go: up one dir, main page]

IS2080B - Mesýlat díhýdrat sölt af 5-(2-(4-(1,2-bensísóþíazól-3-ýl)-1-píperazinýl)-etýl-6-klóró-1,3-díhýdró-2(1H)-indól-2-ón (=zíprasídón), framleiðsla þess ognotkun þess sem dópamín D2 mótlyfs - Google Patents

Mesýlat díhýdrat sölt af 5-(2-(4-(1,2-bensísóþíazól-3-ýl)-1-píperazinýl)-etýl-6-klóró-1,3-díhýdró-2(1H)-indól-2-ón (=zíprasídón), framleiðsla þess ognotkun þess sem dópamín D2 mótlyfs

Info

Publication number
IS2080B
IS2080B IS4874A IS4874A IS2080B IS 2080 B IS2080 B IS 2080B IS 4874 A IS4874 A IS 4874A IS 4874 A IS4874 A IS 4874A IS 2080 B IS2080 B IS 2080B
Authority
IS
Iceland
Prior art keywords
onen
benzisothiazol
ziprasidone
dopamine
piperazinyl
Prior art date
Application number
IS4874A
Other languages
English (en)
Other versions
IS4874A (is
Inventor
Robert Busch Frank
Anne Rose Carol
James Shine Russell
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS4874A publication Critical patent/IS4874A/is
Publication of IS2080B publication Critical patent/IS2080B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
IS4874A 1996-05-07 1998-10-20 Mesýlat díhýdrat sölt af 5-(2-(4-(1,2-bensísóþíazól-3-ýl)-1-píperazinýl)-etýl-6-klóró-1,3-díhýdró-2(1H)-indól-2-ón (=zíprasídón), framleiðsla þess ognotkun þess sem dópamín D2 mótlyfs IS2080B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1675796P 1996-05-07 1996-05-07
PCT/IB1997/000393 WO1997042191A1 (en) 1996-05-07 1997-04-10 Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist

Publications (2)

Publication Number Publication Date
IS4874A IS4874A (is) 1998-10-20
IS2080B true IS2080B (is) 2006-02-15

Family

ID=21778804

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4874A IS2080B (is) 1996-05-07 1998-10-20 Mesýlat díhýdrat sölt af 5-(2-(4-(1,2-bensísóþíazól-3-ýl)-1-píperazinýl)-etýl-6-klóró-1,3-díhýdró-2(1H)-indól-2-ón (=zíprasídón), framleiðsla þess ognotkun þess sem dópamín D2 mótlyfs

Country Status (40)

Country Link
US (1) US6245765B1 (is)
EP (1) EP0918772B1 (is)
JP (1) JP3494659B2 (is)
KR (1) KR100333215B1 (is)
CN (1) CN1091769C (is)
AP (1) AP765A (is)
AR (1) AR007004A1 (is)
AT (1) ATE278689T1 (is)
AU (1) AU731267B2 (is)
BG (1) BG63544B1 (is)
BR (1) BR9709889A (is)
CA (1) CA2252898C (is)
CO (1) CO4940466A1 (is)
CZ (1) CZ289215B6 (is)
DE (1) DE69731094T2 (is)
DK (1) DK0918772T3 (is)
DZ (1) DZ2222A1 (is)
EA (1) EA001190B1 (is)
EG (1) EG24076A (is)
ES (1) ES2229342T3 (is)
GT (1) GT199700052A (is)
HR (1) HRP970236B1 (is)
ID (1) ID16867A (is)
IL (1) IL126591A (is)
IS (1) IS2080B (is)
MA (1) MA24171A1 (is)
MY (1) MY119997A (is)
NO (1) NO312514B1 (is)
NZ (1) NZ332218A (is)
OA (1) OA10909A (is)
PL (1) PL188330B1 (is)
PT (1) PT918772E (is)
SI (1) SI0918772T1 (is)
SK (1) SK282837B6 (is)
TN (1) TNSN97074A1 (is)
TR (1) TR199802240T2 (is)
TW (1) TW491847B (is)
UA (1) UA46840C2 (is)
WO (1) WO1997042191A1 (is)
ZA (1) ZA973876B (is)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
DE60124791T2 (de) * 2000-06-02 2007-09-13 Pfizer Products Inc., Groton S-Methyl-Dihydro-Ziprasidone zur Behandlung von psychiatrischen Störungen.
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
CN1791430A (zh) * 2003-05-16 2006-06-21 辉瑞产品公司 非典型抗精神病药物和gaba调节剂、抗惊厥药物或苯并二氮杂䓬类的治疗性组合
WO2005035531A1 (en) * 2003-06-03 2005-04-21 Teva Paharmaceutical Industries Ltd. POLYMORPHIC FORMS OF ZIPRASIDONE HCl AND PROCESSES FOR THEIR PREPARATION
US7667037B2 (en) 2003-10-24 2010-02-23 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
BRPI0510942A (pt) * 2004-05-11 2007-07-17 Pfizer Prod Inc combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
EA200701065A1 (ru) * 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
US20070032511A1 (en) * 2005-02-11 2007-02-08 Judith Aronhime Amorphous ziprasidone mesylate
WO2006086787A1 (en) * 2005-02-11 2006-08-17 Teva Pharmaceutical Industries Ltd. Process of preparing ziprasidone mesylate
EP1855651A4 (en) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd NANOPARTICLE COMPOSITIONS OF HETEROCYCLIC AMID DERIVATIVES
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
US20060270685A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Anhydrous ziprasidone mesylate and a process for its preparation
EP1858891A2 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
JP2010527925A (ja) * 2007-05-18 2010-08-19 サイドース・エルエルシー ジプラシドン製剤
WO2009156889A1 (en) * 2008-06-25 2009-12-30 Pfizer Inc. Diaryl compounds and uses thereof
WO2012053654A1 (en) * 2010-10-18 2012-04-26 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
NZ508303A (en) 1996-05-07 2001-07-27 Pfizer Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (ziprasidone) useful as a dopamine D2 antagonist

Also Published As

Publication number Publication date
HRP970236B1 (en) 2002-12-31
BG63544B1 (bg) 2002-04-30
DK0918772T3 (da) 2005-01-10
EA001190B1 (ru) 2000-12-25
BG102892A (en) 1999-09-30
NO312514B1 (no) 2002-05-21
NO985194D0 (no) 1998-11-06
EP0918772B1 (en) 2004-10-06
PT918772E (pt) 2004-12-31
EA199800912A1 (ru) 1999-04-29
PL329884A1 (en) 1999-04-12
CA2252898C (en) 2003-04-08
JPH11509867A (ja) 1999-08-31
JP3494659B2 (ja) 2004-02-09
CN1091769C (zh) 2002-10-02
OA10909A (en) 2001-10-26
TNSN97074A1 (fr) 2005-03-15
WO1997042191A1 (en) 1997-11-13
HK1017892A1 (en) 1999-12-03
ID16867A (id) 1997-11-20
AR007004A1 (es) 1999-10-13
TW491847B (en) 2002-06-21
US6245765B1 (en) 2001-06-12
HRP970236A2 (en) 1998-06-30
DE69731094D1 (de) 2004-11-11
TR199802240T2 (is) 1999-02-22
DE69731094T2 (de) 2006-02-23
EP0918772A1 (en) 1999-06-02
MA24171A1 (fr) 1997-12-31
ES2229342T3 (es) 2005-04-16
CZ349398A3 (cs) 1999-09-15
SK282837B6 (sk) 2002-12-03
AP765A (en) 1999-09-17
ATE278689T1 (de) 2004-10-15
CO4940466A1 (es) 2000-07-24
MY119997A (en) 2005-08-30
AU2174797A (en) 1997-11-26
IL126591A0 (en) 1999-08-17
AU731267B2 (en) 2001-03-29
SK150898A3 (en) 2000-02-14
NO985194L (no) 1998-11-06
CA2252898A1 (en) 1997-11-13
KR20000010824A (ko) 2000-02-25
KR100333215B1 (ko) 2002-06-20
IS4874A (is) 1998-10-20
UA46840C2 (uk) 2002-06-17
AP9700976A0 (en) 1997-07-31
DZ2222A1 (fr) 2002-12-03
ZA973876B (en) 1998-11-06
CN1216991A (zh) 1999-05-19
PL188330B1 (pl) 2005-01-31
BR9709889A (pt) 1999-08-10
SI0918772T1 (en) 2005-02-28
NZ332218A (en) 2005-02-25
GT199700052A (es) 2001-08-29
IL126591A (en) 2001-11-25
CZ289215B6 (cs) 2001-12-12
EG24076A (en) 2008-05-11

Similar Documents

Publication Publication Date Title
IS4874A (is) Mesýlat díhýdrat sölt af 5-(2-(4-(1,2-bensísóþíazól-3-ýl)-1-píperazinýl)-etýl-6-klóró-1,3-díhýdró-2(1H)-indól-2-ón (=zíprasídón), framleiðsla þess ognotkun þess sem dópamín D2 mótlyfs
IS2301B (is) Mesýlat tríhýdrat salt af 5-(2-(4(1,2-bensísóþíasól-3-ýl)-1-píperasínýl)etýl)-6-klóró-1,3-díhýdró-2(1H)-indól-2-ón(=síprasidón), framleiðsla þess og notkun þess sem dópamín D2 mótlyf
FI933804L (fi) Monohydrat av 5-(2-(4-(1,2-bensisotiazol-3-yl)-1-piperazinyl)etyl-6-klor-1,3-dihydro-2H-indol-2-onkhydroklorid
DK1349855T3 (da) 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)thiazolidin-2,4-dionmesylatsalt
CO5170422A1 (es) Nuevos compuestos antidiabeticos con base en hidrato de hidrocloruro
HUP9902404A3 (en) Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-choloro-1,3-dihydro-2(2h)-indol-2-one (-ziprasidone), its preparation and its use as dopamine d2 antagonist
DK1556378T3 (da) Acylderivater af 5-(2-(4-(1,2 benzisothiazol-3-yl)-1piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indo-2-on med neuroleptisk aktivitet
DK1315723T3 (da) Hydrochloridsaltet af 5[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dion
IS6758A (is) Kristallaform af 1-[6-klór-5-(tríflúormetýl)-2-pýridinýl]piperasín.hýdróklóríði
NO20031435D0 (no) Natriumsalter av 5-'4-'2-(N-metyl--(2- pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion
HK1095273A (en) Combination of (a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2methylphenyl]-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the use thereof